| Literature DB >> 28732027 |
Ewa Śliwicka1, Tomasz Cisoń2, Zbigniew Kasprzak1, Alicja Nowak1, Łucja Pilaczyńska-Szcześniak1.
Abstract
Exposure to high-altitude hypoxia causes physiological and metabolic adaptive changes by disturbing homeostasis. Hypoxia-related changes in skeletal muscle affect the closely interconnected energy and regeneration processes. The balance between protein synthesis and degradation in the skeletal muscle is regulated by several molecules such as myostatin, cytokines, vitamin D, and irisin. This study investigates changes in irisin and myostatin levels in male climbers after a 2-week high-altitude expedition, and their association with 25(OH)D and indices of inflammatory processes. The study was performed in 8 men aged between 23 and 31 years, who participated in a 2-week climbing expedition in the Alps. The measurements of body composition and serum concentrations of irisin, myostatin, 25(OH)D, interleukin-6, myoglobin, high-sensitivity C-reactive protein, osteoprotegerin, and high-sensitivity soluble receptor activator of NF-κB ligand (sRANKL) were performed before and after expedition. A 2-week exposure to hypobaric hypoxia caused significant decrease in body mass, body mass index (BMI), free fat mass and irisin, 25-Hydroxyvitamin D levels. On the other hand, significant increase in the levels of myoglobin, high-sensitivity C-reactive protein, interleukin-6, and osteoprotegerin were noted. The observed correlations of irisin with 25(OH)D levels, as well as myostatin levels with inflammatory markers and the OPG/RANKL ratio indicate that these myokines may be involved in the energy-related processes and skeletal muscle regeneration in response to 2-week exposure to hypobaric hypoxia.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28732027 PMCID: PMC5521782 DOI: 10.1371/journal.pone.0181259
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Somatic parameters of the participants before and after the high-altitude climbing expedition.
| Variable | Before expedition | After expedition | Δ [%] | ||
|---|---|---|---|---|---|
| 72.3±6.05 | 71.4 (67.9–78.2) | 70.7±5.18 | 70.0 (66.8–74.5) | -2.2 | |
| 22.7±1.27 | 22.7 (21.7–23.7) | 22.2±0.83 | 22.2 (21.5–23.0) | -2.2 | |
| 84.2±2.36 | 84.6 (83.5–85.8) | 84.1±2.78 | 83.8 (83.4–86.2) | -0.1 | |
| 60.9±5.80 | 60.6 (56.2–66.6) | 59.5±5.13 | 58.7 (55.6–64.5) | -2.3 | |
| 15.8±2.36 | 15.5 (14.2–16.5) | 15.9±2.78 | 16.2 (13.8–16.7) | +0.6 | |
| 11.4±1.61 | 11.6 (10.3–12.3) | 11.2±1.89 | 11.3 (10.0–12.3) | -1.8 | |
| 57.8±1.84 | 58.0 (57.3–59.1) | 57.9±2.30 | 57.9 (56.6–59.7) | +0.2 | |
Data are presented as mean ± SD and Me (Q1–Q3). BM, body mass; BMI, body mass index; FFM, fat free mass; FM, fat mass.
* P < 0.05, significant change from baseline.
Fig 1Changes in A: Myoglobin, B: hsCRP and C: IL-6 levels after 2-week exposure to hypobaric hypoxia.
Values are means ± SD. * P < 0.05, significant change from baseline.
Fig 2Changes in A: OPG, B: sRANKL levels and C: OPG/sRANKL ratio after 2-week exposure to hypobaric hypoxia.
Values are means ± SD. * P < 0.05, significant change from baseline.
Fig 3Changes in A: 25(OH)D, B: Irisin and C: Myostatin levels after 2-week exposure to hypobaric hypoxia.
Values are means ± SD. * P < 0.05, significant change from baseline.